

LA JOLLA PHARMACEUTICAL CO
Form 8-K
March 30, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 25, 2005

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

Delaware

0-24274

33-0361285

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

6455 Nancy Ridge Drive, San Diego,
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(858) 452-6600

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On March 25, 2005, William E. Engbers informed La Jolla Pharmaceutical Company (the "Company") that he intends to retire from the Company's board of directors and all committees and related positions thereof, effective upon the expiration of his term at the Company's 2005 annual meeting of stockholders. Accordingly, Mr. Engbers will not stand for re-election as a director at the Company's 2005 annual meeting of stockholders, which is presently scheduled for May 19, 2005. Mr. Engbers has served as a director of the Company since 1991. In connection with this action, the board of directors resolved to reduce the size of the board of directors from six members to five members at the effective time of Mr. Engbers retirement. Mr. Engbers' retirement from the board of directors did not involve any disagreement with the Company.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

La Jolla Pharmaceutical Company

March 29, 2005

By: */s/ Steven B. Engle*

Name: Steven B. Engle

Title: Chairman and Chief Executive Officer